These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 25714363

  • 1. Serology for trachoma surveillance after cessation of mass drug administration.
    Martin DL, Bid R, Sandi F, Goodhew EB, Massae PA, Lasway A, Philippin H, Makupa W, Molina S, Holland MJ, Mabey DC, Drakeley C, Lammie PJ, Solomon AW.
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003555. PubMed ID: 25714363
    [Abstract] [Full Text] [Related]

  • 2. Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger.
    Kim JS, Oldenburg CE, Cooley G, Amza A, Kadri B, Nassirou B, Cotter SY, Stoller NE, West SK, Bailey RL, Keenan JD, Gaynor BD, Porco TC, Lietman TM, Martin DL.
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007127. PubMed ID: 30689671
    [Abstract] [Full Text] [Related]

  • 3. Surveillance Surveys for Reemergent Trachoma in Formerly Endemic Districts in Nepal From 2 to 10 Years After Mass Drug Administration Cessation.
    West SK, Zambrano AI, Sharma S, Mishra SK, Muñoz BE, Dize L, Crowley K, Gaydos CA, Rotondo LA.
    JAMA Ophthalmol; 2017 Nov 01; 135(11):1141-1146. PubMed ID: 28973295
    [Abstract] [Full Text] [Related]

  • 4. The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma.
    Gwyn S, Nute AW, Sata E, Tadesse Z, Chernet A, Haile M, Zeru T, Bethea D, Laurent C, Callahan EK, Nash SD, Martin DL.
    Am J Trop Med Hyg; 2021 Aug 16; 105(5):1362-1367. PubMed ID: 34398819
    [Abstract] [Full Text] [Related]

  • 5. Serology, infection, and clinical trachoma as tools in prevalence surveys for re-emergence of trachoma in a formerly hyperendemic district.
    Odonkor M, Naufal F, Munoz B, Mkocha H, Kasubi M, Wolle M, West S.
    PLoS Negl Trop Dis; 2021 Apr 16; 15(4):e0009343. PubMed ID: 33861754
    [Abstract] [Full Text] [Related]

  • 6. Pgp3 seroprevalence and associations with active trachoma and ocular Chlamydia trachomatis infection in Malawi: cross-sectional surveys in six evaluation units.
    Burr SE, Hart J, Samikwa L, Chaima D, Cooley G, Martin D, Masika M, Solomon AW, Bailey RL, Kalua K.
    PLoS Negl Trop Dis; 2019 Oct 16; 13(10):e0007749. PubMed ID: 31658258
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
    Wilson N, Goodhew B, Mkocha H, Joseph K, Bandea C, Black C, Igietseme J, Munoz B, West SK, Lammie P, Kasubi M, Martin DL.
    Ophthalmic Epidemiol; 2019 Feb 16; 26(1):1-6. PubMed ID: 30543311
    [Abstract] [Full Text] [Related]

  • 8. Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati.
    Cama A, Müller A, Taoaba R, Butcher RMR, Itibita I, Migchelsen SJ, Kiauea T, Pickering H, Willis R, Roberts CH, Bakhtiari A, Le Mesurier RT, Alexander NDE, Martin DL, Tekeraoi R, Solomon AW, Global Trachoma Mapping Project.
    PLoS Negl Trop Dis; 2017 Sep 16; 11(9):e0005863. PubMed ID: 28898240
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of Chlamydia trachomatis-Specific Antibodies before and after Mass Drug Administration for Trachoma in Community-Wide Surveys of Four Communities in Nepal.
    Gwyn SE, Xiang L, Kandel RP, Dean D, Gambhir M, Martin DL.
    Am J Trop Med Hyg; 2018 Jan 16; 98(1):216-220. PubMed ID: 29141720
    [Abstract] [Full Text] [Related]

  • 10. Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool for National Trachoma Control Programs? Results from a District Survey.
    West SK, Munoz B, Weaver J, Mrango Z, Dize L, Gaydos C, Quinn TC, Martin DL.
    PLoS Negl Trop Dis; 2016 Jan 16; 10(1):e0004352. PubMed ID: 26771906
    [Abstract] [Full Text] [Related]

  • 11. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
    Last AR, Burr SE, Harding-Esch E, Cassama E, Nabicassa M, Roberts CH, Mabey DCW, Holland MJ, Bailey RL.
    Parasit Vectors; 2017 Dec 28; 10(1):624. PubMed ID: 29282126
    [Abstract] [Full Text] [Related]

  • 12. Serological and PCR-based markers of ocular Chlamydia trachomatis transmission in northern Ghana after elimination of trachoma as a public health problem.
    Senyonjo LG, Debrah O, Martin DL, Asante-Poku A, Migchelsen SJ, Gwyn S, deSouza DK, Solomon AW, Agyemang D, Biritwum-Kwadwo N, Marfo B, Bakajika D, Mensah EO, Aboe A, Koroma J, Addy J, Bailey R.
    PLoS Negl Trop Dis; 2018 Dec 28; 12(12):e0007027. PubMed ID: 30550537
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal change in the serology of antibodies to Chlamydia trachomatis pgp3 in children residing in a trachoma area.
    West SK, Munoz B, Kaur H, Dize L, Mkocha H, Gaydos CA, Quinn TC.
    Sci Rep; 2018 Feb 23; 8(1):3520. PubMed ID: 29476106
    [Abstract] [Full Text] [Related]

  • 14. Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
    Ervin AM, Mkocha H, Munoz B, Dreger K, Dize L, Gaydos C, Quinn TC, West SK.
    Ophthalmic Epidemiol; 2016 Dec 23; 23(6):347-353. PubMed ID: 27820670
    [Abstract] [Full Text] [Related]

  • 15. Serological Responses to Trachoma Antigens prior to the Start of Mass Drug Administration: Results from Population-Based Baseline Surveys, North Darfur, Sudan.
    Sanders AM, Elshafie BE, Abdalla Z, Simmons C, Goodhew EB, Gonzalez TA, Nute AW, Mohammed A, Callahan EK, Martin DL, Nash SD.
    Am J Trop Med Hyg; 2024 Sep 03; 111(3_Suppl):49-57. PubMed ID: 38507810
    [Abstract] [Full Text] [Related]

  • 16. Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration.
    Goodhew EB, Morgan SM, Switzer AJ, Munoz B, Dize L, Gaydos C, Mkocha H, West SK, Wiegand RE, Lammie PJ, Martin DL.
    BMC Infect Dis; 2014 Apr 22; 14():216. PubMed ID: 24755001
    [Abstract] [Full Text] [Related]

  • 17. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J, Munoz B, Mkocha H, Gaydos CA, Bailey R, Lietman TA, Quinn T, West SK.
    JAMA Ophthalmol; 2013 Apr 22; 131(4):431-6. PubMed ID: 23392481
    [Abstract] [Full Text] [Related]

  • 18. Surveillance for peri-elimination trachoma recrudescence: Exploratory studies in Ghana.
    Senyonjo L, Addy J, Martin DL, Agyemang D, Yeboah-Manu D, Gwyn S, Marfo B, Asante-Poku A, Aboe A, Mensah E, Solomon AW, Bailey RL.
    PLoS Negl Trop Dis; 2021 Sep 22; 15(9):e0009744. PubMed ID: 34543293
    [Abstract] [Full Text] [Related]

  • 19. Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma Program.
    Pant BP, Bhatta RC, Chaudhary JS, Awasthi S, Mishra S, Sharma S, Cuddapah PA, Gwyn SE, Stoller NE, Martin DL, Keenan JD, Lietman TM, Gaynor BD.
    PLoS Negl Trop Dis; 2016 Feb 22; 10(2):e0004462. PubMed ID: 26871898
    [Abstract] [Full Text] [Related]

  • 20. Population-based prevalence survey of follicular trachoma and trachomatous trichiasis in the Casamance region of Senegal.
    Harding-Esch EM, Kadimpeul J, Sarr B, Sane A, Badji S, Laye M, Sillah A, Burr SE, MacLeod D, Last AR, Holland MJ, Mabey DC, Bailey RL.
    BMC Public Health; 2017 Jul 26; 18(1):62. PubMed ID: 28747198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.